In cell experiments, both Rituximab/saporin-S6 conjugates showed a strong effect on the two CD20+ lymphoma-derived cell lines, causing a complete block of protein synthesis at a concentration significantly higher for LMW-IT than for HMW-IT. The gene discussed is MS4A1; the disease is lymphoma.